What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially report Regeneron Pharmaceuticals, Inc.'s financial and operating results for the first quarter ended March 31, 2013, by furnishing the accompanying press release.

Where can I find the detailed financial and operational results for Q1 2013?

The detailed financial and operational results for Q1 2013 are contained within the press release dated May 3, 2013, which is attached as Exhibit 99.1 to this Form 8-K filing.

Does this 8-K filing contain new strategic announcements or significant business updates?

This specific 8-K filing is primarily for reporting quarterly financial results. While the press release (Exhibit 99.1) may contain operational updates, significant new strategic announcements are not explicitly detailed within the 8-K text itself. Investors should carefully review the press release for any such information.

When were Regeneron's Q1 2013 results officially announced?

Regeneron's Q1 2013 results were announced on May 3, 2013, the same date this 8-K filing was made and the press release was issued.

REGN 8-K: Earnings & Results

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on May 3, 2013, to report its financial and operating results for the first quarter ended March 31, 2013. This filing primarily serves to furnish the official press release containing these key performance indicators and operational updates to the Securities and Exchange Commission. Investors should refer to the press release (Exhibit 99.1) for detailed information regarding Regeneron's financial health, revenue generation, and strategic advancements during the first quarter of 2013. This includes insights into product sales, research and development progress, and any significant corporate developments that could impact the company's future performance and stock valuation.

Key Highlights

1Filing of Form 8-K on May 3, 2013, to report Q1 2013 financial and operating results.
2Announcement of Q1 2013 financial and operating results via press release.
3Press release attached as Exhibit 99.1 to the 8-K filing.
4The filing is made pursuant to Item 2.02 (Results of Operations and Financial Condition).
5Investors are directed to the press release for specific financial and operational details.
6Indicates a routine reporting event for the company's quarterly performance.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 3, 2013)

Summary

Key Highlights

Frequently Asked Questions